Scarica l'app Stockscreener
13.02
3.12%
-0.42
Dopo l'orario di chiusura:
13.00
-0.02
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$13.44
Aprire:
$13.44
Volume 24 ore:
3.99M
Relative Volume:
0.77
Capitalizzazione di mercato:
$10.39B
Reddito:
$220.00K
Utile/perdita netta:
$-1.21B
Rapporto P/E:
-8.1177
EPS:
-1.6039
Flusso di cassa netto:
$-387.48M
1 W Prestazione:
-4.69%
1M Prestazione:
-10.64%
6M Prestazione:
-10.08%
1 anno Prestazione:
-50.63%
Intervallo 1D:
$13.01
$13.59
Intervallo di 1 settimana:
$12.25
$14.23
Portata 52W:
$12.25
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.02 | 10.45B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics stock hits 52-week low at 12.52 USD By Investing.com - Investing.com Canada
SMMT|Summit Therapeutics Inc|Price:13.105|Chg%:-0.555 - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm - Morningstar
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Cash Flow - TradingKey
Summit Therapeutics officers investigated for p... - Pluang
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations - The Globe and Mail
Piper Sandler Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Summit Therapeutics Establishes $380 Million ATM Equity Program - The Globe and Mail
Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept - marketscreener.com
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 - BioSpace
Guggenheim lowers Summit Therapeutics stock price target on trial timing By Investing.com - Investing.com Canada
Summit Therapeutics Signs Distribution Agreement With J.P. Morgan Securities for Common Stock Offering - Minichart
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Benzinga
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Yahoo Finance
Summit (SMMT) Completes Enrollment in Global HARMONi-3 Study - GuruFocus
Summit Therapeutics (SMMT) Reports Q2 EPS Beat with Strong Cash Position - GuruFocus
Summit Q2 2026 slides: ivonescimab OS data strengthens amid spending rise - Investing.com Nigeria
Summit Therapeutics (SMMT) Faces Financial Uncertainty Amid Funding Challenges - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Clinical Developments and Strong Cash Position - GuruFocus
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: - GuruFocus
Summit Therapeutics Launches $380 Million At-the-Market Equity Offering Program with J.P. Morgan Securities - Kalkine Media
Summit Therapeutics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Summit Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Summit (SMMT) Advances Clinical Trials with Promising Ivonescima - GuruFocus
Summit Therapeutics (SMMT) Faces Funding Challenges Amid Q2 Losses - GuruFocus
Concerns Rise for Summit Therapeutics (SMMT) Regarding Financial Viability - GuruFocus
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain? - Yahoo Finance
SMMT Q2 FY2026 earnings call - finance.biggo.com
[SMMT Q2 2026 Earnings Call] Summit Therapeutics Cash Hits $690.7M, Updated HARMONi Data Shows HR 0.76 Overall Survival Ahead of PDUFA - finance.biggo.com
Summit Therapeutics Initiates $380 Million At-The-Market Stock Offering with J.P. Morgan - Kalkine Media
Earnings call transcript: Summit Therapeutics Q2 2026 loss widens as shares fall after hours - Investing.com Canada
SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Summit Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SMMT) 2026-07-23 - Seeking Alpha
Summit Therapeutics Q2 Earnings Call Highlights - TradingView
Transcript : Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):